- Home
- GRFX vs NXTC Comparison
GRFX vs NXTC Comparison
Compare GRFX & NXTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GRFX
- NXTC
- Stock Information
- Founded
- GRFX 1981
- NXTC 2015
- Country
- GRFX Hong Kong
- NXTC United States
- Employees
- GRFX N/A
- NXTC N/A
- Industry
- GRFX
- NXTC Biotechnology: Pharmaceutical Preparations
- Sector
- GRFX
- NXTC Health Care
- Exchange
- GRFX Nasdaq
- NXTC Nasdaq
- Market Cap
- GRFX 18.1M
- NXTC 20.6M
- IPO Year
- GRFX N/A
- NXTC 2019
- Fundamental
- Price
- GRFX $1.01
- NXTC $0.30
- Analyst Decision
- GRFX Hold
- NXTC Strong Buy
- Analyst Count
- GRFX 1
- NXTC 2
- Target Price
- GRFX N/A
- NXTC $3.50
- AVG Volume (30 Days)
- GRFX 46.9K
- NXTC 120.8K
- Earning Date
- GRFX 01-01-0001
- NXTC 05-01-2025
- Dividend Yield
- GRFX N/A
- NXTC N/A
- EPS Growth
- GRFX N/A
- NXTC N/A
- EPS
- GRFX N/A
- NXTC N/A
- Revenue
- GRFX $24,184,100.00
- NXTC N/A
- Revenue This Year
- GRFX N/A
- NXTC N/A
- Revenue Next Year
- GRFX N/A
- NXTC N/A
- P/E Ratio
- GRFX N/A
- NXTC N/A
- Revenue Growth
- GRFX N/A
- NXTC N/A
- 52 Week Low
- GRFX $0.71
- NXTC $0.27
- 52 Week High
- GRFX $2.75
- NXTC $2.09
- Technical
- Relative Strength Index (RSI)
- GRFX 43.26
- NXTC 16.75
- Support Level
- GRFX $0.95
- NXTC $0.35
- Resistance Level
- GRFX $1.24
- NXTC $0.67
- Average True Range (ATR)
- GRFX 0.26
- NXTC 0.08
- MACD
- GRFX -0.02
- NXTC -0.02
- Stochastic Oscillator
- GRFX 19.21
- NXTC 0.27
About GRFX Graphex Group Limited each representing 20
Graphex Group Ltd is engaged in the sale of graphene products. It operates in three segments namely, the Graphene Products Segment includes Processing and sale of graphite and graphene-related products; the Landscape Architecture Design Segment includes Providing landscape architecture design; and the catering business focuses on the operation of restaurants. The company derives the majority of its revenue from the sale of graphene products segment.
About NXTC NextCure Inc.
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases, and NC181, for Alzheimer's disease.